DMXD-011

N/A

Report date: 2025/01/27 13:17:34
NME

Base Information

Drug NameDMXD-011
Drug Alias NameIKK-epsilon/TBK 1 inhibitors (Domainex/Breakthrough Breast Cancer)IKK-epsilon/TBK 1 inhibitors (Domainex/Breakthrough Breast Cancer)WEHI‐112IKK-epsilon/TBK 1 inhibitors (Domainex/Breakthrough Breast Cancer/Institute of Cancer Research)DMXD-011
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase TBK1 inhibitorsInhibitor of nuclear factor kappa-B kinase subunit epsilon inhibitors
TargetsSerine/threonine-protein kinase TBK1Inhibitor of NF-kappa-B kinase (IKK)Inhibitor of nuclear factor kappa-B kinase subunit epsilon
Therapy Area/IndicationsInflammationScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBreakthrough Breast Cancer
China Registration ClassN/A

Develop Information

Active CompaniesDomainex Ltd
Inactive CompaniesBreakthrough Breast CancerInstitute Of Cancer Research
Active IndicationsInflammationScleroderma, SystemicLupus Erythematosus, Systemic +[4] 
Inactive IndicationsOvarian NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A